The WAVE trial was designed to evaluate the efficacy ... The proportion of AVG patients who were free from an adverse event was higher than the safety PG (95.4% vs. 89.0%, p=0.0162).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback